Evidence map›Paper›PMID 35972684›Full record

ArticleJournal of nephrology2022

Screening for Fabry disease in Argentina in male patients with chronic kidney disease at all stages.

Choua Martin, Neumann Pablo, Quieto Pedro, Rozenfeld Paula, Argentine renal group on Fabry disease

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Choua MartinAADELFA, La Plata, Argentina.
Neumann PabloServicio de Nefrología, Ipensa, La Plata, Argentina.
Quieto PedroAADELFA, La Plata, Argentina.
Rozenfeld PaulaAADELFA, La Plata, Argentina. paularozenfeld@gmail.com.ORCID 0000-0002-8138-3087
Argentine renal group on Fabry disease

Funding

AADELFA AADELFA1
6 · The paper itself

Abstract

We report three patients diagnosed with Fabry disease through a screening study which included individuals suffering from chronic kidney disease (CKD) at any stage. The study recruited 1740 male patients, and three Fabry patients were diagnosed, resulting in a frequency of 0.17%. The analysis by CKD stage group revealed frequencies of 3.03%, 0.77% and 0.17%, in CKD1, CKD3 and CKD5, respectively. Pedigree analysis was carried out for these families, with a high ratio index: pedigree (1:16). This study underlines the importance of considering Fabry disease in the differential diagnosis at every stage of CKD, including the early ones, and stresses the possibility of finding patients with late onset phenotypes.

Indexed as

Fabry DiseaseRenal Insufficiency, Chronicalpha-GalactosidaseArgentinaHumansMaleMass ScreeningPedigreealpha-GalactosidaseAlpha galactosidase AChronic kidney diseaseFabry diseaseHigh risk screening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.